lomefloxacin has been researched along with Bronchitis in 9 studies
lomefloxacin: structure given in first source
lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
Bronchitis: Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Comparative efficacy of lomefloxacin (400 mg daily for 5 days) and roxithromycin (150 mg daily for 5 days) was studied in the treatment of 24 patients (12 males and 12 females) at the age of 39 to 83 years (the average age of 59 years) with exacerbation of chronic obstructive bronchitis." | 9.08 | [Efficacy of lomefloxacin in treatment of patients with chronic bronchitis]. ( Bykova, AV; Emel'ianov, AV; Fedoseev, GB; Rudinskiĭ, KA; Shevelev, SE, 1998) |
| "Nine centers in Italy participated in a worldwide, multicenter study comparing the effectiveness and safety of lomefloxacin and amoxicillin in patients with acute exacerbations of chronic bronchitis caused mainly by gram-negative pathogens." | 9.07 | Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study. ( Albera, C; Grassi, C; Pozzi, E, 1992) |
| "In two multicenter trials, lomefloxacin and cefaclor were compared as treatments for acute bacterial exacerbations of chronic bronchitis." | 9.07 | Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis. ( Ellison, WT; Gotfried, MH, 1992) |
| "Lomefloxacin is a difluorinated quinolone with excellent activity against a wide range of pathogens including those responsible for acute exacerbations of chronic bronchitis (AECB)." | 7.71 | Safety and effectiveness of lomefloxacin in patients with acute exacerbation of chronic bronchitis (AECB) chronically treated with oral theophyllines. ( Cantoni, V; Melani, AS; Pirrelli, M; Sarlo, F, 2001) |
| "Lomefloxacin has been shown to produce high and sustained concentrations in serum and bronchial mucosa after once-daily administration." | 6.67 | A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology. ( Kemper, P; Köhler, D, 1992) |
| "Comparative efficacy of lomefloxacin (400 mg daily for 5 days) and roxithromycin (150 mg daily for 5 days) was studied in the treatment of 24 patients (12 males and 12 females) at the age of 39 to 83 years (the average age of 59 years) with exacerbation of chronic obstructive bronchitis." | 5.08 | [Efficacy of lomefloxacin in treatment of patients with chronic bronchitis]. ( Bykova, AV; Emel'ianov, AV; Fedoseev, GB; Rudinskiĭ, KA; Shevelev, SE, 1998) |
| "Nine centers in Italy participated in a worldwide, multicenter study comparing the effectiveness and safety of lomefloxacin and amoxicillin in patients with acute exacerbations of chronic bronchitis caused mainly by gram-negative pathogens." | 5.07 | Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study. ( Albera, C; Grassi, C; Pozzi, E, 1992) |
| "In two multicenter trials, lomefloxacin and cefaclor were compared as treatments for acute bacterial exacerbations of chronic bronchitis." | 5.07 | Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis. ( Ellison, WT; Gotfried, MH, 1992) |
| "Results of trials of lomefloxacin (400 mg once daily) in elderly patients with uncomplicated urinary tract infections, complicated urinary tract infections, acute bacterial exacerbations of chronic bronchitis, and as prophylaxis for transurethral surgical procedures (400 mg single dose) have been analyzed." | 4.78 | Infection in the elderly: studies with lomefloxacin. ( Bruce-Jones, P; Crome, P, 1992) |
| "Lomefloxacin is a difluorinated quinolone with excellent activity against a wide range of pathogens including those responsible for acute exacerbations of chronic bronchitis (AECB)." | 3.71 | Safety and effectiveness of lomefloxacin in patients with acute exacerbation of chronic bronchitis (AECB) chronically treated with oral theophyllines. ( Cantoni, V; Melani, AS; Pirrelli, M; Sarlo, F, 2001) |
| "Lomefloxacin has been shown to produce high and sustained concentrations in serum and bronchial mucosa after once-daily administration." | 2.67 | A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology. ( Kemper, P; Köhler, D, 1992) |
| "Lomefloxacin is a new fluoroquinolone antimicrobial agent that has undergone extensive worldwide clinical evaluation." | 2.38 | The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone. ( Rizk, E, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (88.89) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fedoseev, GB | 1 |
| Emel'ianov, AV | 1 |
| Rudinskiĭ, KA | 1 |
| Shevelev, SE | 1 |
| Bykova, AV | 1 |
| Iakovlev, SV | 1 |
| Belousov, IuB | 1 |
| Efremenkova, OV | 1 |
| Sokolov, AV | 1 |
| Tishenkova, IF | 1 |
| Melani, AS | 1 |
| Pirrelli, M | 1 |
| Sarlo, F | 1 |
| Cantoni, V | 1 |
| Grassi, C | 1 |
| Albera, C | 1 |
| Pozzi, E | 1 |
| Gotfried, MH | 1 |
| Ellison, WT | 1 |
| Crome, P | 1 |
| Bruce-Jones, P | 1 |
| Rizk, E | 1 |
| Kemper, P | 1 |
| Köhler, D | 1 |
2 reviews available for lomefloxacin and Bronchitis
| Article | Year |
|---|---|
Infection in the elderly: studies with lomefloxacin.
Topics: Aged; Aging; Anti-Infective Agents; Bacterial Infections; Bronchitis; Female; Fluoroquinolones; Huma | 1992 |
The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Fluoroquinolones; Humans; Meta-Analysis as | 1992 |
6 trials available for lomefloxacin and Bronchitis
| Article | Year |
|---|---|
[Efficacy of lomefloxacin in treatment of patients with chronic bronchitis].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bronchitis; Chronic Di | 1998 |
[Pharmacodynamic and pharmacokinetic approaches to optimization of lomefloxacin].
Topics: Age Factors; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Escherichia coli; Fluoroquino | 1998 |
[The importance of fluoroquinolones in treating pneumonia in the elderly].
Topics: Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Dose-Response Relationship, Drug; Fluoroqu | 1999 |
Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study.
Topics: Acute Disease; Aged; Amoxicillin; Anti-Infective Agents; Bronchitis; Chi-Square Distribution; Chroni | 1992 |
Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Cefaclor; Chronic | 1992 |
A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Chi-Square Distribution; Chronic | 1992 |
1 other study available for lomefloxacin and Bronchitis
| Article | Year |
|---|---|
Safety and effectiveness of lomefloxacin in patients with acute exacerbation of chronic bronchitis (AECB) chronically treated with oral theophyllines.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Infective Agents; Bronchitis; Cross-Sectional | 2001 |